Drug Chatter -- Tracking biopharma stock chatter

💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…

Profile for Neurocrine Biosciences, Inc. (NBIX)

« Back to company index

NBIX Chatter Timeline

Stock Ticker for NBIX

Most Active Tweeters for NBIX

UserTweets
@mediasentiment 11
@MarcJacksonLA 6
@Estimize 4
@Allstocknews 4
@newsfilterio 4

Recent Tweets for NBIX

mediasentiment @mediasentiment
$NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 204
May 8th 2021, 1:05pm
ResearchPool @ResearchPool
$NBIX #Neurocrine Biosciences Inc. Continued Ingrezza Weakness, But Think It Can Turn A Corner: [...]… https://t.co/tOwPnI4s83
May 8th 2021, 1:05pm
mediasentiment @mediasentiment
$NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 37
May 8th 2021, 8:05am
mediasentiment @mediasentiment
$NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 972
May 7th 2021, 9:05pm
Jarvis_Alerts @Jarvis_Alerts
$NBIX [Neurocrine Biosciences]: SVB Leerink Maintains Market Perform Lowers Price Target $110 --> 100 https://t.co/g0Ybj2if7z
May 7th 2021, 12:05pm
Jarvis_Alerts @Jarvis_Alerts
$NBIX [Neurocrine Biosciences]: Morgan Stanley Maintains Overweight Lowers Price Target $125 --> 116 https://t.co/lK9goG1mt2
May 7th 2021, 12:05pm
WallstWhispers @WallstWhispers
We understand Barclays analyst Carter Gould upgraded Neurocrine Biosciences $NBIX to Overweight from Equal Weight w… https://t.co/8TJycRQ7jP
May 6th 2021, 9:05pm
BioMedReports @BioMedReports
Barclays analyst Carter Gould upgraded Neurocrine Biosciences $NBIX to Overweight from Equal Weight with an unchang… https://t.co/67BPZ3iHOz
May 6th 2021, 9:05pm
mediasentiment @mediasentiment
$NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 722
May 6th 2021, 7:05pm
newsfilterio @newsfilterio
Neurocrine upgraded at Barclays despite Q1 earnings miss $NBIX https://t.co/bM5Rfr6K2j
May 6th 2021, 3:05pm
MarketCurrents @MarketCurrents
$NBIX - Neurocrine upgraded at Barclays despite Q1 earnings miss https://t.co/Z26alvBAQi
May 6th 2021, 3:05pm
mediasentiment @mediasentiment
$NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 479
May 6th 2021, 2:05pm
MarcJacksonLA @MarcJacksonLA
$NBIX HC Wainwright Maintains Buy Rating On Neurocrine Biosciences, $140 PT https://t.co/IOOgwHmXmW
May 6th 2021, 2:05pm
MarcJacksonLA @MarcJacksonLA
$NBIX Oppenheimer Assigns a Buy Rating On Neurocrine Biosciences, $140 PT https://t.co/5ooyGyaYv5
May 6th 2021, 2:05pm
MarcJacksonLA @MarcJacksonLA
$NBIX Barclays Upgrades Neurocrine Biosciences To Overweight From Equal Weight, $110 PT https://t.co/5knw0DdPkl
May 6th 2021, 1:05pm
HoganMullally @HoganMullally
RT @encodelp: $NBIX remains on track to initiate two studies with NBI-921352, Nav1.6 antagonist licensed from $XENE, this year https://t.co…
May 6th 2021, 12:05pm
Jarvis_Alerts @Jarvis_Alerts
$NBIX [Neurocrine Biosciences]: Barclays Upgrades Equal-Weight --> Overweight Announces Price Target $110 https://t.co/K4CCv1ZW7W
May 6th 2021, 12:05pm
QuantData @QuantData
Barclays Upgrades Neurocrine Biosciences to Overweight, Announces $110 Price Target Related Tickers: $NBIX Read mo… https://t.co/9sXDIil57h
May 6th 2021, 11:05am
newsfilterio @newsfilterio
$NBIX Barclays analyst Carter Gould upgrades Neurocrine Biosciences from Equal-Weight to Overweight and announces $110 price target.
May 6th 2021, 11:05am
Briefingcom @Briefingcom
$NBIX: Barclays ups to Overweight
May 6th 2021, 10:05am
BioWino @BioWino
RT @sbwcws: Neurocrine upgraded to Overweight from Equal Weight at Barclays $NBIX
May 6th 2021, 10:05am
sbwcws @sbwcws
Neurocrine upgraded to Overweight from Equal Weight at Barclays $NBIX
May 6th 2021, 10:05am
SiteFocusHQ @SiteFocusHQ
$NBIX Earnings Intelligence Analysis of recent earnings identified Neurocrine Biosciences, Inc (NASDAQ: NBIX ) busi… https://t.co/sG5TTW2TIu
May 6th 2021, 4:05am
EarningsAlley @EarningsAlley
Neurocrine Biosciences, Inc. $NBIX held an earnings call on 5/5/2021. Here are the highlights:
May 6th 2021, 4:05am
SeekingAlpha @SeekingAlpha
$NBIX - Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript.… https://t.co/FtaatQQC2i
May 6th 2021, 1:05am
SeekingAlpha @SeekingAlpha
$NBIX - Neurocrine Biosciences, Inc. 2021 Q1 - Results - Earnings Call Presentation. https://t.co/YBCAI4xWQl #trading #stockmarket #economy
May 6th 2021, 1:05am
EdgarInsider @EdgarInsider
Alert [Press/News Current Report] / Form 8-K filed with the SEC $NBIX NEUROCRINE BIOSCIENCES INC https://t.co/DfCck87Miv
May 5th 2021, 10:05pm
EdgarInsider @EdgarInsider
Filing for 10-Q [Quarterly Report] has been made with the SEC: $NBIX NEUROCRINE BIOSCIENCES INC https://t.co/gMQ5yDRbJQ
May 5th 2021, 10:05pm
Briefingcom @Briefingcom
$NBIX: Neurocrine Biosci misses by $0.29, misses on revs https://t.co/uBC0BAvCdn
May 5th 2021, 10:05pm
mediasentiment @mediasentiment
$NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 1048
May 5th 2021, 8:05pm
Estimize @Estimize
The most accurate $NBIX estimate is from Canaccord_163, beating 10 other analysts and the Wall Street Consensus - https://t.co/Eb9ymd3H90
May 5th 2021, 8:05pm
Estimize @Estimize
$NBIX misses the Estimize EPS Consensus by 42c and the Estimize Revenue Consensus by $14.69M. Reports FQ1 earnings… https://t.co/LG29e8Xuy9
May 5th 2021, 8:05pm
Estimize @Estimize
$NBIX reports FQ1 earnings of 33c EPS and $236.60M Revs - https://t.co/GbaaAakJx1
May 5th 2021, 8:05pm
Allstocknews @Allstocknews
$NBIX New Form 10-Q for Neurocrine Biosciences, Inc. From our Stock News Alerts App
May 5th 2021, 8:05pm
encodelp @encodelp
$NBIX remains on track to initiate two studies with NBI-921352, Nav1.6 antagonist licensed from $XENE, this year https://t.co/OyZ29SsOWo
May 5th 2021, 8:05pm
otcdynamics @otcdynamics
$NBIX Neurocrine Biosciences Reports First Quarter 2021 Financial Results https://t.co/pmmdVAoeDC
May 5th 2021, 8:05pm
mediasentiment @mediasentiment
$NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 868
May 5th 2021, 8:05pm
Sanctuary_Bio @Sanctuary_Bio
$NBIX Ingrezza sales down for a 3rd quarter in a role, Ongentys flat sequentially (~$1M), increases opex guidance f… https://t.co/YPqcgQJAou
May 5th 2021, 8:05pm
fintel_io @fintel_io
$NBIX / Neurocrine Biosciences files form 10-Q https://t.co/zFgofVxyvg
May 5th 2021, 8:05pm
Allstocknews @Allstocknews
$NBIX Neurocrine Biosciences Reports First Quarter 2021 Financial Results From our Stock News Alerts App
May 5th 2021, 8:05pm
MarcJacksonLA @MarcJacksonLA
$NBIX Neurocrine Biosciences Reports 1Q 2021 Results https://t.co/yZh4S6pLfI
May 5th 2021, 8:05pm
fintel_io @fintel_io
$NBIX / Neurocrine Biosciences files form 8-K - Financial Statements and Exhibits, Results of Operations and Financ… https://t.co/kuL4wYgUnH
May 5th 2021, 8:05pm
FlashAlert_me @FlashAlert_me
$NBIX [15s. delayed] filed form 8-K on May 05, 16:05:00: Item2.02: Results of Operations & Financial Condition https://t.co/Oy14AL4wWj
May 5th 2021, 8:05pm
glitchbotio @glitchbotio
RT @MarketCurrents: $NBIX - Neurocrine Biosciences EPS misses by $0.24, misses on revenue https://t.co/R0BhGKkCVz
May 5th 2021, 8:05pm
MSollender @MSollender
$NBIX Neurocrine Biosciences Reports First Quarter 2021 Financial Results INGREZZA® (valbenazine) First Quarter 20… https://t.co/aE0jGbgfUz
May 5th 2021, 8:05pm
MarketCurrents @MarketCurrents
$NBIX - Neurocrine Biosciences EPS misses by $0.24, misses on revenue https://t.co/R0BhGKkCVz
May 5th 2021, 8:05pm
stock_titan @stock_titan
$NBIX Neurocrine Biosciences Reports First Quarter 2021 Financial Results https://t.co/jKkNiQLN0R
May 5th 2021, 8:05pm
tinkStrategy @tinkStrategy
RT @Sanctuary_Bio: should be a fun AH $NBIX - stabilization in Ingrezza sales (2 quarters in decline)? Traction on Ongentys? $OCUL - Dexte…
May 5th 2021, 7:05pm
earningsinfo @earningsinfo
$NBIX Neurocrine Biosciences Inc Q1 2021 Earnings Call https://t.co/cpGhfMwUmG
May 5th 2021, 7:05pm
AccesswireNews @AccesswireNews
$NBIX Neurocrine Biosciences, Inc. to Host Earnings Call https://t.co/5OF61jAeum
May 5th 2021, 6:05pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2021. All rights reserved.